Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    AIM ImmunoTech Inc (AIM) Insider Trading Activity

    Healthcare • Biotechnology • 26 employees

    AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

    Total Value

    $226,036.73

    Total Shares

    922,909

    Average Trade Value

    $9,418.20

    Most Active Insider

    Equels Thomas K

    Total Activity: $144,512

    Largest Single Transaction

    $100,000

    by Equels Thomas K on Sep 11, 2024

    30-Day Activity

    2 Transactions

    Volume: 51,594 shares
    Value: $10,417

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Director
    Jan 31, 2025 25,797 $5,208 198,063 (+13.0%) Grant
    Director
    Jan 31, 2025 25,797 $5,208 165,073 (+15.6%) Grant
    Director
    Jan 15, 2025 27,412 $5,208 172,226 (+15.9%) Grant
    Director
    Jan 15, 2025 27,412 $5,208 139,276 (+19.7%) Grant
    Director
    Dec 31, 2024 26,305 $5,208 111,864 (+23.5%) Grant
    Director
    Dec 31, 2024 8,768 $1,736 388,729 (+2.3%) Grant
    Director
    Dec 31, 2024 26,305 $5,208 144,854 (+18.2%) Grant
    Director
    Dec 19, 2024 4,580 $884 118,549 (-3.9%) Sale
    CEO President
    Director, Officer
    Dec 18, 2024 22,727 $4,682 1,680,695 (+1.4%) Purchase
    Director
    Dec 13, 2024 24,452 $5,208 85,559 (+28.6%) Grant
    Director
    Dec 13, 2024 24,452 $5,208 379,961 (+6.4%) Grant
    Director
    Dec 13, 2024 24,452 $5,208 123,803 (+19.8%) Grant
    Director
    Dec 2, 2024 22,645 $5,208 344,397 (+6.6%) Grant
    Director
    Dec 2, 2024 11,111 $2,356 355,509 (+3.1%) Purchase
    Director
    Dec 2, 2024 1 $0 344,398 (+0.0%) Purchase
    Director
    Dec 2, 2024 22,645 $5,208 99,351 (+22.8%) Grant
    Director
    Dec 2, 2024 22,645 $5,208 61,107 (+37.1%) Grant
    CEO President
    Director, Officer
    Nov 21, 2024 20,000 $4,240 1,657,968 (+1.2%) Purchase
    CEO President
    Director, Officer
    Nov 20, 2024 60,110 $11,000 1,552,968 (+3.9%) Purchase
    CEO President
    Director, Officer
    Nov 20, 2024 85,000 $16,915 1,637,968 (+5.2%) Purchase
    Director
    Nov 20, 2024 81,953 $15,817 321,752 (+25.5%) Purchase
    CEO President
    Director, Officer
    Sep 16, 2024 5,000 $1,515 1,493,042 (+0.3%) Purchase
    CEO President
    Director, Officer
    Sep 13, 2024 20,000 $6,160 1,488,042 (+1.3%) Purchase
    CEO President
    Director, Officer
    Sep 11, 2024 312,500 $100,000 1,468,042 (+21.3%) Grant